

Freedom of Information Request

Reference Number: [EPUT.FOI.22.2453](#)
Date Received: [01.04.2022](#)

Information Requested:

1. In the past 3 months (or the latest 3 months data you have available), how many Metastatic/advanced Breast cancer patients were treated with:
 - Abemaciclib (Verzenios) + aromatase inhibitor *
 - Abemaciclib (Verzenios) + Fulvestrant (Faslodex)
 - Alpelisib (Piqray) + Fulvestrant (Faslodex)
 - Atezolizumab (Tecentriq)**
 - Bevacizumab (Avastin)
 - Eribulin (Halaven)
 - Everolimus (Afinitor) + Exemestane
 - Fulvestrant (Faslodex) as a single agent
 - Gemcitabine + paclitaxel
 - Herceptin (Trastuzumab) + paclitaxel
 - Herceptin (Trastuzumab) as a single agent
 - Lapatinib (Tyverb)
 - Neratinib (Nerlynx)
 - Olaparib (Lynparza)
 - Palbociclib (Ibrance) + aromatase inhibitor*
 - Palbociclib (Ibrance) + Fulvestrant (Faslodex)
 - Pertuzumab (Perjeta) + trastuzumab + docetaxel
 - Ribociclib (Kisqali) + aromatase inhibitor*
 - Ribociclib (Kisqali) + Fulvestrant (Faslodex)
 - Talazoparib (Talzenna)

- Trastuzumab emtansine (Kadcyla)
- Other active systemic anti-cancer therapy **

*aromatase inhibitor eg. Anastrozole, Exemestane or Letrozole

**eg. docetaxel, vinorelbine or capecitabine as a single agent

2. For the above patients, how many of these received their first ever dose for each product line?

Response:

Essex Partnership University NHS Foundation Trust is a Mental Health, Learning Disability and Community Services Trust and does not offer these services.

Publication Scheme:

As part of the Freedom of Information Act all public organisations are required to proactively publish certain classes of information on a Publication Scheme. A publication scheme is a guide to the information that is held by the organisation. EPUT's Publication Scheme is located on its Website at the following link <https://eput.nhs.uk>